We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
Location: United States, Massachusetts, Woburn
Employees: 11-50
Total raised: $105M
Founded date: 2012
Investors 3
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | OrbiMed | orbimed.co... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.08.2021 | Series B | $60M | - |
| 04.01.2018 | Series A | $45M | - |
Mentions in press and media 16
| Date | Title | Description | Source |
| 27.08.2021 | Daily funding roundup - August 26th, 2021 | Picsart has raised $130M; Neurogastrx landed $60M; Recuro Health secured $15M Picsart: Picsart is a... | vator.tv/n... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Ex... | Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative thera... | marketscre... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Ex... | - | orbimed.co... |
| 26.08.2021 | Neurogastrx assembles ex-Ironwood team with $60M to take on ... | Neurogastrx thinks its late-stage acid reflux drug and another midstage gastrointestinal treatment c... | fiercebiot... |
| 26.08.2021 | Neurogastrx Secures $60M in Series B Financing | - | vivocapita... |
| 26.08.2021 | Neurogastrx assembles ex-Ironwood team with $60M to take on ... | Neurogastrx thinks its late-stage acid reflux drug and another midstage gastrointestinal treatment c... | fiercebiot... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Ex... | - | vivocapita... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Ex... | - | 5amventure... |
| 26.08.2021 | After pandemic delay and a South Korean deal, Boston-a... | Two years after snaring a $45 million Series A from a couple of top-flight investors, Neurog... | endpts.com... |
| 08.06.2021 | Neurogastrx Announces Agreement with Daewoong Pharmaceutical... | WOBURN, Mass., June 8, 2021 /PRNewswire/ -- Neurogastrx, Inc., a privately held specialty pharmace... | prnewswire... |
Show more